1.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 18 to 65
Sponsor: Other
Protocol IDs: EudraCT:2005-000805-68, NCT00354120
|
|
2.
|
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CAM307, NCT00046683
|
|
3.
|
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CAM314, 2004-000149-39, NCT00086580
|
|
4.
|
Phase: Phase III
Type: Supportive care, Treatment
Status: Completed
Age: 12 to 65
Sponsor: Other
Protocol IDs: PROGAST, NCT00180089
|
|
5.
|
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: CDR0000577580, CLL-2007-FMP, INCA-RECF0496, EudraCT-2007-000327-18, RECF0496, NCT00564512
|
|
6.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 15 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000302482, U10CA031946, CALGB-10102, NCT00061945
|
|
7.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: Not specified
Sponsor: Other
Protocol IDs: 12472, ACHE, BCM-H-12472, H 12472, BCM-ACHE, NCT00056966
|
|
8.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 0 to 70
Sponsor: Other
Protocol IDs: H8714, DIMSUM, NCT00048412
|
|
9.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 to 60
Sponsor: NCI
Protocol IDs: CALGB-100102, NCT00085449
|
|
10.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 to 65
Sponsor: Other, Pharmaceutical / Industry
Protocol IDs: GCLLSG-CLL3X, EU-20554, MEDAC-FLUD.10/CLL, NCT00281983
|
|
11.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: 05-404, NCT00330252
|
|
12.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 to 55
Sponsor: NCI, Other
Protocol IDs: LCCC 0510, P30CA016086, CDR0000550145, UNC-LCCC-0510, NCT00448357
|
|
13.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: Over 15
Sponsor: Other
Protocol IDs: P051003, NCT00773149
|
|
14.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 to 75
Sponsor: Other
Protocol IDs: 14341B, NCT00943592
|
|
15.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 16 to 120
Sponsor: Other
Protocol IDs: 090331, NCT00983528
|
|
16.
|
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: DUMC-1340-99-7, NCI-G99-1617, NCT00004143
|
|
17.
|
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000067506, U10CA031946, CLB-19901, CALGB-19901, NCT00004857
|
|
18.
|
Phase: Phase II
Type: Treatment
Status: Completed
Age: 70 and under
Sponsor: NCI
Protocol IDs: MSKCC-01092, NCI-G01-2028, NCT00027560
|
|
19.
|
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: 030194, 03-C-0194, NCI-03-C-0194, NCI-4553, 4553, NCT00064155, NCT00061048
|
|
20.
|
Phase: Phase II
Type: Treatment
Status: Closed
Age: Under 70
Sponsor: Other
Protocol IDs: BCM-H-10857, NCT00069992
|
|
21.
|
Phase: Phase II
Type: Treatment
Status: Completed
Age: Over 18
Sponsor: NCI, Other
Protocol IDs: CDR0000358811, UCLA-0309058, NCT00081068
|
|
22.
|
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: BRLX-FLUCAM106, BRLX-STA1-03-058, OHSU-HEM-03050-P, DMS-F0334, NCT00086775
|
|
23.
|
Phase: Phase II
Type: Treatment
Status: Completed
Age: 15 and over
Sponsor: Other
Protocol IDs: ID02-368, NCT00071396
|
|
24.
|
Phase: Phase II
Type: Treatment
Status: Completed
Age: 30 and under at diagnosis
Sponsor: NCI
Protocol IDs: COG-ADVL0222, ADVL0222, NCI-05-C-0248, NCT00089349
|
|
25.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000398139, U10CA031946, CALGB-10101, NCT00098670
|
Mobile | Español
